Safety and feasibility of initiating a hepatic artery infusion pump chemotherapy program for unresectable colorectal liver metastases: A multicenter, retrospective cohort study.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Chemotherapy, Adjuvant
/ mortality
Colorectal Neoplasms
/ drug therapy
Feasibility Studies
Female
Follow-Up Studies
Hepatic Artery
Humans
Infusion Pumps, Implantable
Infusions, Intra-Arterial
/ methods
Liver Neoplasms
/ drug therapy
Male
Middle Aged
Prognosis
Retrospective Studies
Survival Rate
colorectal liver metastasis
hepatic artery infusion pump chemotherapy
liver metastases treatment
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
20
08
2020
revised:
06
10
2020
accepted:
08
10
2020
pubmed:
24
10
2020
medline:
12
1
2021
entrez:
23
10
2020
Statut:
ppublish
Résumé
Hepatic artery infusion pump (HAIP) chemotherapy is a specialized therapy for patients with unresectable colorectal liver metastases (uCRLM). Its effectiveness was demonstrated from a high volume center, with uncertainty regarding the feasibility and safety at other centers. Therefore, we sought to assess the safety and feasibility of HAIP for the management of uCRLM at other centers. We conducted a multicenter retrospective cohort study of patients with uCRLM treated with HAIP from January 2003 to December 2017 at six North American centers initiating the HAIP program. Outcomes included the safety and feasibility of HAIP chemotherapy. We identified 154 patients with HAIP insertion and the median age of 54 (48-61) years. The burden of disease was >10 intra-hepatic metastatic foci in 59 (38.3%) patients. Patients received at least one cycle of systemic chemotherapy before HAIP insertion. Major complications occurred in 7 (4.6%) patients during their hospitalization and 13 (8.4%) patients developed biliary sclerosis during follow-up. A total of 148 patients (96.1%) received at least one-dose of HAIP chemotherapy with a median of 5 (4-7) cycles. 78 patients (56.5%) had a complete or partial response and 12 (7.8%) received a curative liver resection. HAIP programs can be safely and effectively initiated in previously inexperienced centers with good response.
Identifiants
pubmed: 33095919
doi: 10.1002/jso.26270
pmc: PMC8749357
mid: NIHMS1766791
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
252-260Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Surg Oncol. 2020 Dec;27(13):5086-5095
pubmed: 32779054
Ann Oncol. 2014 Jan;25(1):107-16
pubmed: 24356622
J Clin Oncol. 1984 Jun;2(6):595-600
pubmed: 6233400
BMC Cancer. 2019 Apr 5;19(1):327
pubmed: 30953467
Curr Oncol. 2014 Feb;21(1):e129-36
pubmed: 24523610
Arch Surg. 1984 Aug;119(8):936-41
pubmed: 6378147
Ann Surg Oncol. 2008 Jan;15(1):219-26
pubmed: 17896145
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Curr Oncol. 2014 Feb;21(1):e116-21
pubmed: 24523608
World J Surg. 2010 Apr;34(4):797-807
pubmed: 20054541
Lancet. 2003 Feb 1;361(9355):368-73
pubmed: 12573372
JAMA Oncol. 2020 Jan 1;6(1):60-67
pubmed: 31670750
J Natl Cancer Inst. 1951 Aug;12(1):107-31
pubmed: 14874125
J Clin Oncol. 1996 Apr;14(4):1128-35
pubmed: 8648367
J Clin Oncol. 2001 May 15;19(10):2687-95
pubmed: 11352961
Semin Oncol. 1983 Jun;10(2):176-82
pubmed: 6346495
Ann Surg Oncol. 2019 Dec;26(13):4599-4607
pubmed: 31641947
J Clin Oncol. 2009 Jul 20;27(21):3465-71
pubmed: 19470932
Ann Surg. 2015 Feb;261(2):353-60
pubmed: 24646562
Mol Cancer Ther. 2009 May;8(5):1015-25
pubmed: 19383854
Colorectal Dis. 2012 Aug;14(8):920-30
pubmed: 21899714
J Clin Oncol. 1994 Nov;12(11):2288-95
pubmed: 7964942
J Clin Oncol. 2000 Jan;18(2):243-54
pubmed: 10637236
J Am Coll Surg. 2005 Jul;201(1):57-65
pubmed: 15978444
Ann Surg Oncol. 2012 May;19(5):1609-17
pubmed: 21989666
Semin Oncol. 2010 Apr;37(2):139-48
pubmed: 20494706
J Clin Oncol. 1992 Jul;10(7):1112-8
pubmed: 1296590
Ann Intern Med. 1987 Oct;107(4):459-65
pubmed: 2957943
Ann Oncol. 2003;14 Suppl 2:ii13-6
pubmed: 12810452
Int J Colorectal Dis. 2008 Jun;23(6):559-68
pubmed: 18330581
N Engl J Med. 1999 Dec 30;341(27):2039-48
pubmed: 10615075
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
J Clin Oncol. 2003 Jun 1;21(11):2059-69
pubmed: 12775730
J Surg Oncol. 2018 Mar;117(4):634-643
pubmed: 29165816
J Clin Oncol. 2008 Dec 10;26(35):5721-7
pubmed: 19001325
Ann Surg Oncol. 2020 Dec;27(13):5098-5106
pubmed: 32740732
Surg Clin North Am. 2016 Apr;96(2):341-55
pubmed: 27017868
Eur J Surg Oncol. 2000 Aug;26(5):468-73
pubmed: 11016468